Compare Manhattan Associates Inc (MANH) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Manhattan Associates Inc vs Merck & Co., Inc. — how do they compare? Manhattan Associates Inc trades at $205.35 (market cap $12.06B), while Merck & Co., Inc. trades at $145.85 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 29.1× Manhattan Associates Inc's market cap, and Merck & Co., Inc. pays a 2.39% dividend while Manhattan Associates Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Manhattan Associates Inc for 12 Days and Merck & Co., Inc. for 98 Days on average.
| MANH | MRK | |
|---|---|---|
Market Cap | $12.06B | $351.28B |
Volume | 376,150 | 7,969,665 |
Sector | Technology | Health |
52-Week High | $223.76 | $156.43 |
52-Week Low | $120.88 | $82.49 |
Typical Hold Time | 12 Days | 98 Days |
Enterprise Value | $11.93B | $398.04B |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Manhattan Associates (MANH) trades at $202.11, down 0.36% with bearish technical signals but strong fundamentals. The stock shows robust profitability with 18.67% net margins and consistent earnings beats, though valuation multiples appear elevated. Recent news includes a law firm investigation into fiduciary duties and a downgrade to neutral by DA Davidson, while the company launched new solution editions to expand market reach.
The outlook balances strong operational performance against high valuation and legal scrutiny. Upside potential exists from continued earnings momentum and product innovation, but risks include the ongoing investigation and competitive pressures. Analyst consensus remains bullish with a $210.50 price target, suggesting modest upside from current levels.
Merck (MRK) trades at $144.96, up 1.52% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 72.97% gross margin and 28.07% net income margin for 2025, though its P/E ratio of 113.9 indicates high valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid competitive pressures.
The outlook is mixed: analyst consensus is bullish with a $158.78 price target, but technical indicators and a high P/E suggest near-term caution. Key risks include integration challenges from acquisitions and macroeconomic headwinds affecting pharmaceutical R&D investment. Revenue growth and pipeline execution remain critical for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Manhattan Associates Inc
Manhattan Associates, Inc. is a global leader in supply chain and omnichannel commerce software. The company provides a comprehensive suite of cloud-based and on-premise solutions for warehouse management (WMS), transportation management (TMS), and order management (OMS). MANH's technology helps retailers, wholesalers, and manufacturers manage inventory, optimize logistics, and unify the shopping experience across physical and digital channels.
Read more on MANH →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
